Whole Exome Sequencing vs. Whole Genome Sequencing for FFPE Samples
Formalin-fixed, paraffin-embedded (FFPE) samples are commonly used in clinical diagnostics and biomedical research because they preserve tissue structure and allow long-term storage. Many retrospective studies rely on these archived samples.
However, FFPE processing can damage DNA. Formalin fixation may fragment DNA, cause cross-linking, and chemically alter bases, leading to shorter fragments and potential sequencing errors. If these issues aren’t addressed, it becomes more difficult to accurately identify genetic variants.
Given these challenges, the choice of sequencing method, whole exome sequencing vs. whole genome sequencing, can greatly influence the quality and reliability of data from FFPE DNA. Some approaches handle short or damaged fragments better, affecting coverage uniformity, artifact filtering, and overall usable data.
Laboratories must therefore select a sequencing strategy that aligns with sample quality, research objectives, and clinical needs. This article compares whole exome sequencing vs. whole genome sequencing performance specifically for FFPE samples.
What Are FFPE Samples and Why Do They Impact Sequencing Quality?
FFPE samples account for approximately 70% of all pathology samples, highlighting their importance in clinical diagnostics and research. These tissues are preserved with formalin to stabilize structure and embedded in paraffin to allow thin-section cutting for microscopic analysis, making them common in clinical archives.
However, formalin fixation can compromise DNA integrity. Cross-links form between DNA and proteins, strands break into shorter fragments over time, and chemical modifications to bases may occur, all of which can interfere with accurate sequencing.
Short, fragmented DNA from FFPE samples poses challenges for sequencing. It complicates alignment, can cause uneven coverage, and increases the likelihood of dropouts in low-complexity regions, making variant detection more difficult.
Sequencing method design plays a key role in performance. Targeted approaches, such as amplicon-based or hybrid capture, are generally more effective for FFPE DNA because they enrich specific regions, increasing the likelihood of usable reads from degraded samples. By contrast, broader approaches such as whole genome sequencing may capture more DNA overall. Still, they can produce higher background noise and less efficient detection of relevant sequences when the DNA is damaged.
Whole Exome Sequencing (WES)
Whole exome sequencing focuses on the protein-coding regions of the genome, which represent a small fraction of total DNA but contain many variants linked to disease. WES uses capture probes to select exons before sequencing, limiting data to regions with clear clinical relevance.
Coverage depth is a key advantage of WES. Most clinical tests achieve high read depth in targeted regions, which increases confidence in variant detection, especially in degraded samples such as those from FFPE tissue. The smaller dataset also makes analysis and storage more manageable.
Clinical oncology teams often rely on WES for tumor profiling, as many actionable mutations occur within exons. This focus aids in treatment selection and biomarker discovery, and FFPE-derived DNA is generally well-suited to this approach.
DNA quality impacts sequencing performance. FFPE samples frequently contain short, fragmented DNA, which targeted capture methods handle more effectively than whole genome sequencing. By concentrating reads on relevant regions, WES maximizes usable data and improves reliability.
Overall, whole exome sequencing offers a practical balance of depth, sensitivity, and data quality. In situations where FFPE-derived DNA is challenging, WES often outperforms broader approaches, making it a preferred choice in the whole exome sequencing vs. whole genome sequencing debate.
Whole Genome Sequencing (WGS)
Whole genome sequencing examines the entire DNA sequence of a sample, including both coding and non-coding regions. In contrast, whole exome sequencing targets only protein-coding genes, so the scope of data and depth of analysis differ significantly.
When comparing whole genome vs. whole exome sequencing, WGS generates much more data because it covers the entire genome rather than selected regions. This broader coverage often results in lower average depth per region unless additional sequencing is performed. DNA from normal FFPE samples typically performs less efficiently than DNA from fresh tissue, underscoring the importance of this depth difference.
WGS can identify a wider range of variants, including structural changes, copy-number variations, and variants in non-coding regions. However, FFPE-derived DNA can introduce noise across the genome, requiring careful artifact filtering to maintain accuracy.
Research teams commonly use WGS for discovery-focused studies and translational research, especially when investigating regulatory regions or genomic changes beyond the exome.
DNA Quality and Library Preparation for FFPE Samples
Coverage and Data Quality: WES vs. WGS in FFPE Samples
Coverage uniformity is a common challenge in FFPE sequencing. DNA fragmentation and chemical damage can create uneven read distribution, with some regions overrepresented and others missed. These issues are more pronounced in FFPE samples compared to fresh or frozen tissue.
Whole exome sequencing addresses these challenges through targeted capture. Probes enrich coding regions before sequencing, increasing usable coverage from short DNA fragments. Higher read depth also increases confidence in variant detection.
Whole genome sequencing distributes reads across the entire genome. When DNA quality is low, this can reduce the average depth per region. FFPE-induced damage adds background noise, alignment errors, and more frequent dropout in low-complexity regions.
Data consistency differs between methods. WES generally achieves higher on-target rates and more uniform depth across captured regions, improving reproducibility across FFPE samples. WGS covers the entire genome but can suffer from lower effective depth and more variable results when DNA is degraded.
Choosing the right method depends on the study goals and the quality of the sample. In the whole genome vs. whole exome sequencing comparison, WES often performs better with FFPE samples due to its targeted depth, consistency, and more reliable downstream interpretation.
Variant Detection Performance in FFPE Samples
The accuracy of variant detection depends heavily on the quality of FFPE DNA. Short fragments and chemical damage can make alignment difficult, increasing the risk of false positives and complicating the confirmation of single-nucleotide variants (SNVs) and small insertions or deletions (indels).
Artifact management is key to reliable results. FFPE processing often induces C-to-T transitions that mimic real somatic mutations, so bioinformatics pipelines must apply strict filtering, remove duplicates, and check for strand bias to reduce errors.
The choice of sequencing method affects variant detection. Whole exome sequencing targets coding regions and achieves higher depth in these areas, improving sensitivity for clinically relevant SNVs and indels. Consistent coverage also simplifies variant interpretation.
Whole genome sequencing can detect a broader range of variant types, including structural variants and copy-number changes, but FFPE-related noise affects the entire genome. Lower effective depth can make borderline calls less reliable.
For most clinical applications, especially in oncology, WES often provides more dependable detection of exonic variants in FFPE samples. WGS may still be valuable for broader discovery, but method selection should be guided by sample quality, research objectives, and specific analysis goals, highlighting the practical considerations in the whole genome sequencing vs. exome sequencing debate.
4 Considerations in the WES vs. WGS Debate
When deciding between sequencing methods for FFPE samples, practical factors like cost, speed, and data handling play a key role in method selection:
1. Cost: Whole exome sequencing requires less sequencing depth and generates smaller datasets, making costs more predictable. Whole genome sequencing is more expensive because it produces a larger volume of data.
2. Turnaround Time: WES workflows are generally faster, from library preparation to reporting, because smaller datasets are quicker to process. This speed makes WES a preferred option for routine FFPE testing in clinical labs.
3. Data Interpretation: WGS produces large, complex datasets that require advanced bioinformatics support and increase long-term storage costs. WES data is easier to manage, review, and interpret.
4. Clinical Practicality: For routine FFPE testing, WES offers practical workflows, consistent coverage, and clearer variant interpretation. In whole genome sequencing vs. exome sequencing comparisons, WES often has the advantage in daily clinical practice.
Clinical and Research Use Cases: When WES or WGS Makes More Sense
In oncology, FFPE tumor profiling often favors whole exome sequencing because most actionable mutations occur in coding regions. Higher-depth sequencing improves variant detection in degraded DNA, making WES a practical choice for routine clinical workflows. For research or rare variant discovery, whole genome sequencing can provide broader coverage beyond coding regions, though FFPE DNA quality may limit effective genome-wide analysis.
Retrospective and archival studies also benefit from targeted sequencing, which helps maintain consistent results across samples of varying age and preservation conditions. Ultimately, method selection depends on study goals, sample quality, and practical considerations such as regulatory guidelines and cost factors, which frequently make WES the preferred approach in the whole genome sequencing vs. whole exome sequencing debate.
Which Is Better for FFPE Samples: WES or WGS
Technical trade-offs strongly influence sequencing outcomes. Whole exome sequencing provides higher usable depth from fragmented FFPE DNA and more consistent data interpretation across samples, making it well-suited for most clinical applications.
Whole genome sequencing remains valuable for research-focused studies, especially when a broader genomic context is needed. High-quality input DNA improves WGS results, but FFPE-derived DNA can limit effective genome-wide coverage.
Ultimately, the choice between whole exome sequencing vs. whole genome sequencing should be guided by sample quality, research or clinical goals, and the types of variants of interest. For FFPE samples, laboratories can order products from Superior BioDiagnostics to ensure the highest-quality specimens.
Choosing the Right Approach for FFPE Studies
Whole exome sequencing and whole genome sequencing handle FFPE samples differently. WES provides higher usable depth from fragmented DNA, while WGS covers more of the genome but can show more noise in damaged samples. These differences influence data reliability and variant interpretation.
Labs should align sequencing methods with study goals—clinical oncology often benefits from targeted approaches like WES, while research may require broader WGS analysis if sample quality allows. Optimized FFPE workflows, including DNA extraction, library preparation, and artifact filtering, help ensure consistent, high-quality results.
Superior BioDiagnostics provides US-sourced FFPE samples, including normal, malignant, and disease-state specimens, with detailed clinical information. Using these validated samples helps labs develop reliable sequencing workflows and make confident decisions for FFPE-based studies. Order samples from Superior BioDiagnostics today to get started.
